Monte Rosa Therapeutics (GLUE) Stock: Buy, Sell, or Hold?
GLUE - Monte Rosa Therapeutics, Inc. Common Stock
$14.07
-0.25 (-1.75%)
▼
5d:
-2.16%
30d:
-11.79%
90d:
-17.72%
BUY
HIGH Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GLUE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GLUE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: GLUE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: GLUE is currently trading at $14.07, which is considered slightly low relative to its 30-day fair value range of $14.07 to $15.65.
Technical Outlook: Technically, GLUE is in a downtrend. Immediate support is located at $13.12, while resistance sits at $15.00.
Market Sentiment: GLUE scores 90/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $28.50 (+102.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GLUE is in a downtrend. Immediate support is located at $13.12, while resistance sits at $15.00.
Market Sentiment: GLUE scores 90/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $28.50 (+102.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$14.07 -
$15.65
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (90/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 102.6% below Wall St target ($28.50)
- BULLISH: Bottoming setup score 90/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$14.07 -
$15.65
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$13.12
Resistance Level
$15.00
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.51
Wall Street Target
$28.50
(+102.6%)
Revenue Growth (YoY)
-61.3%
Share & Embed Analysis
Last updated: September 12, 2026 10:15 AM ET
Data refreshes hourly during market hours. Next update: 11:15 AM
Data refreshes hourly during market hours. Next update: 11:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLUE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Philip Nickson
SELL
5845 shares
2026-04-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
Advanced GLUE Option Strategies
Professional options setups generated by AI based on today's GLUE price and gamma walls.
